Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases.

Körbelin J, Dogbevia G, Michelfelder S, Ridder DA, Hunger A, Wenzel J, Seismann H, Lampe M, Bannach J, Pasparakis M, Kleinschmidt JA, Schwaninger M, Trepel M.

EMBO Mol Med. 2016 Jun 1;8(6):609-25. doi: 10.15252/emmm.201506078. Print 2016 Jun.

2.

Pulmonary Targeting of Adeno-associated Viral Vectors by Next-generation Sequencing-guided Screening of Random Capsid Displayed Peptide Libraries.

Körbelin J, Sieber T, Michelfelder S, Lunding L, Spies E, Hunger A, Alawi M, Rapti K, Indenbirken D, Müller OJ, Pasqualini R, Arap W, Kleinschmidt JA, Trepel M.

Mol Ther. 2016 Jun;24(6):1050-1061. doi: 10.1038/mt.2016.62. Epub 2016 Mar 28.

3.

The SUMOylation Pathway Restricts Gene Transduction by Adeno-Associated Viruses.

Hölscher C, Sonntag F, Henrich K, Chen Q, Beneke J, Matula P, Rohr K, Kaderali L, Beil N, Erfle H, Kleinschmidt JA, Müller M.

PLoS Pathog. 2015 Dec 1;11(12):e1005281. doi: 10.1371/journal.ppat.1005281. eCollection 2015 Dec.

4.

Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors.

Trepel M, Körbelin J, Spies E, Heckmann MB, Hunger A, Fehse B, Katus HA, Kleinschmidt JA, Müller OJ, Michelfelder S.

Gene Ther. 2015 Oct;22(10):848. doi: 10.1038/gt.2015.76. No abstract available.

PMID:
26446851
5.

Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors.

Trepel M, Körbelin J, Spies E, Heckmann MB, Hunger A, Fehse B, Katus HA, Kleinschmidt JA, Müller OJ, Michelfelder S.

Gene Ther. 2015 Oct;22(10):840-7. doi: 10.1038/gt.2015.52. Epub 2015 Jun 2. Erratum in: Gene Ther. 2015 Oct;22(10):848.

PMID:
26034897
6.

Parvoviruses cause nuclear envelope breakdown by activating key enzymes of mitosis.

Porwal M, Cohen S, Snoussi K, Popa-Wagner R, Anderson F, Dugot-Senant N, Wodrich H, Dinsart C, Kleinschmidt JA, Panté N, Kann M.

PLoS Pathog. 2013 Oct;9(10):e1003671. doi: 10.1371/journal.ppat.1003671. Epub 2013 Oct 31.

7.

Properties of the adeno-associated virus assembly-activating protein.

Naumer M, Sonntag F, Schmidt K, Nieto K, Panke C, Davey NE, Popa-Wagner R, Kleinschmidt JA.

J Virol. 2012 Dec;86(23):13038-48. doi: 10.1128/JVI.01675-12. Epub 2012 Sep 26.

8.

Impact of capsid modifications by selected peptide ligands on recombinant adeno-associated virus serotype 2-mediated gene transduction.

Naumer M, Popa-Wagner R, Kleinschmidt JA.

J Gen Virol. 2012 Oct;93(Pt 10):2131-41. doi: 10.1099/vir.0.044735-0. Epub 2012 Jul 4.

PMID:
22764318
9.

Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate.

Nieto K, Weghofer M, Sehr P, Ritter M, Sedlmeier S, Karanam B, Seitz H, Müller M, Kellner M, Hörer M, Michaelis U, Roden RB, Gissmann L, Kleinschmidt JA.

PLoS One. 2012;7(6):e39741. doi: 10.1371/journal.pone.0039741. Epub 2012 Jun 27.

10.

The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing.

Raupp C, Naumer M, Müller OJ, Gurda BL, Agbandje-McKenna M, Kleinschmidt JA.

J Virol. 2012 Sep;86(17):9396-408. doi: 10.1128/JVI.00209-12. Epub 2012 Jun 20.

11.

Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry.

Popa-Wagner R, Porwal M, Kann M, Reuss M, Weimer M, Florin L, Kleinschmidt JA.

J Virol. 2012 Sep;86(17):9163-74. doi: 10.1128/JVI.00282-12. Epub 2012 Jun 13.

12.

Nuclear translocation of adeno-associated virus type 2 capsid proteins for virion assembly.

Popa-Wagner R, Sonntag F, Schmidt K, King J, Kleinschmidt JA.

J Gen Virol. 2012 Sep;93(Pt 9):1887-98. doi: 10.1099/vir.0.043232-0. Epub 2012 Jun 13.

PMID:
22694902
13.

Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8.

Gurda BL, Raupp C, Popa-Wagner R, Naumer M, Olson NH, Ng R, McKenna R, Baker TS, Kleinschmidt JA, Agbandje-McKenna M.

J Virol. 2012 Aug;86(15):7739-51. doi: 10.1128/JVI.00218-12. Epub 2012 May 16.

14.

Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques.

Nieto K, Stahl-Hennig C, Leuchs B, Müller M, Gissmann L, Kleinschmidt JA.

Hum Gene Ther. 2012 Jul;23(7):733-41. doi: 10.1089/hum.2011.202. Epub 2012 Apr 18.

15.

Long-term preservation of cardiac structure and function after adeno-associated virus serotype 9-mediated microdystrophin gene transfer in mdx mice.

Schinkel S, Bauer R, Bekeredjian R, Stucka R, Rutschow D, Lochmüller H, Kleinschmidt JA, Katus HA, Müller OJ.

Hum Gene Ther. 2012 Jun;23(6):566-75. doi: 10.1089/hum.2011.017. Epub 2012 Mar 9.

PMID:
22248393
16.

Development and validation of novel AAV2 random libraries displaying peptides of diverse lengths and at diverse capsid positions.

Naumer M, Ying Y, Michelfelder S, Reuter A, Trepel M, Müller OJ, Kleinschmidt JA.

Hum Gene Ther. 2012 May;23(5):492-507. doi: 10.1089/hum.2011.139. Epub 2012 Feb 23.

PMID:
22171602
17.

Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors.

Varadi K, Michelfelder S, Korff T, Hecker M, Trepel M, Katus HA, Kleinschmidt JA, Müller OJ.

Gene Ther. 2012 Aug;19(8):800-9. doi: 10.1038/gt.2011.143. Epub 2011 Sep 29.

PMID:
21956692
18.

The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes.

Sonntag F, Köther K, Schmidt K, Weghofer M, Raupp C, Nieto K, Kuck A, Gerlach B, Böttcher B, Müller OJ, Lux K, Hörer M, Kleinschmidt JA.

J Virol. 2011 Dec;85(23):12686-97. doi: 10.1128/JVI.05359-11. Epub 2011 Sep 14.

19.

Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo.

Michelfelder S, Varadi K, Raupp C, Hunger A, Körbelin J, Pahrmann C, Schrepfer S, Müller OJ, Kleinschmidt JA, Trepel M.

PLoS One. 2011;6(8):e23101. doi: 10.1371/journal.pone.0023101. Epub 2011 Aug 5.

20.

Conformational changes in adeno-associated virus type 1 induced by genome packaging.

Gerlach B, Kleinschmidt JA, Böttcher B.

J Mol Biol. 2011 Jun 10;409(3):427-38. doi: 10.1016/j.jmb.2011.03.062. Epub 2011 Apr 2.

PMID:
21463638
21.

Efficient gene transfer with pseudotyped recombinant adeno-associated viral vectors into human chronic myelogenous leukemia cells.

Sellner L, Veldwijk MR, Kleinschmidt JA, Laufs S, Topaly J, Fruehauf S, Zeller WJ, Wenz F.

Leuk Lymphoma. 2011 Mar;52(3):483-90. doi: 10.3109/10428194.2010.545460.

PMID:
21323526
22.

A viral assembly factor promotes AAV2 capsid formation in the nucleolus.

Sonntag F, Schmidt K, Kleinschmidt JA.

Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10220-5. doi: 10.1073/pnas.1001673107. Epub 2010 May 17.

23.

Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library.

Ying Y, Müller OJ, Goehringer C, Leuchs B, Trepel M, Katus HA, Kleinschmidt JA.

Gene Ther. 2010 Aug;17(8):980-90. doi: 10.1038/gt.2010.44. Epub 2010 Apr 15.

PMID:
20393510
24.

Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.

Nieto K, Kern A, Leuchs B, Gissmann L, Müller M, Kleinschmidt JA.

Antivir Ther. 2009;14(8):1125-37. doi: 10.3851/IMP1469.

PMID:
20032542
25.

Pseudotyped recombinant adeno-associated viral vectors mediate efficient gene transfer into primary human CD34(+) peripheral blood progenitor cells.

Veldwijk MR, Sellner L, Stiefelhagen M, Kleinschmidt JA, Laufs S, Topaly J, Fruehauf S, Zeller WJ, Wenz F.

Cytotherapy. 2010;12(1):107-12. doi: 10.3109/14653240903348293.

PMID:
19929455
26.

Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries.

Michelfelder S, Kohlschütter J, Skorupa A, Pfennings S, Müller O, Kleinschmidt JA, Trepel M.

PLoS One. 2009;4(4):e5122. doi: 10.1371/journal.pone.0005122. Epub 2009 Apr 9.

27.

Prevention of cardiomyopathy in delta-sarcoglycan knockout mice after systemic transfer of targeted adeno-associated viral vectors.

Goehringer C, Rutschow D, Bauer R, Schinkel S, Weichenhan D, Bekeredjian R, Straub V, Kleinschmidt JA, Katus HA, Müller OJ.

Cardiovasc Res. 2009 Jun 1;82(3):404-10. doi: 10.1093/cvr/cvp061. Epub 2009 Feb 13.

PMID:
19218289
28.

Application of a haematopoetic progenitor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line.

Stiefelhagen M, Sellner L, Kleinschmidt JA, Jauch A, Laufs S, Wenz F, Zeller WJ, Fruehauf S, Veldwijk MR.

Genet Vaccines Ther. 2008 Sep 12;6:12. doi: 10.1186/1479-0556-6-12.

29.

Augmentation of AAV-mediated cardiac gene transfer after systemic administration in adult rats.

Müller OJ, Schinkel S, Kleinschmidt JA, Katus HA, Bekeredjian R.

Gene Ther. 2008 Dec;15(23):1558-65. doi: 10.1038/gt.2008.111. Epub 2008 Jul 10.

PMID:
18615116
30.

Generation of efficient human blood progenitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells.

Sellner L, Stiefelhagen M, Kleinschmidt JA, Laufs S, Wenz F, Fruehauf S, Zeller WJ, Veldwijk MR.

Exp Hematol. 2008 Aug;36(8):957-64. doi: 10.1016/j.exphem.2008.03.007. Epub 2008 May 20.

PMID:
18495326
31.

Augmented transgene expression in transformed cells using a parvoviral hybrid vector.

Krüger L, Eskerski H, Dinsart C, Cornelis J, Rommelaere J, Haberkorn U, Kleinschmidt JA.

Cancer Gene Ther. 2008 Apr;15(4):252-67. doi: 10.1038/sj.cgt.7701113. Epub 2008 Jan 18.

PMID:
18202715
32.

Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors.

Raake PW, Hinkel R, Müller S, Delker S, Kreuzpointner R, Kupatt C, Katus HA, Kleinschmidt JA, Boekstegers P, Müller OJ.

Gene Ther. 2008 Jan;15(1):12-7. Epub 2007 Oct 18.

PMID:
17943147
33.

Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy.

Michelfelder S, Lee MK, deLima-Hahn E, Wilmes T, Kaul F, Müller O, Kleinschmidt JA, Trepel M.

Exp Hematol. 2007 Dec;35(12):1766-76. Epub 2007 Oct 17.

PMID:
17920758
34.

Development of AAV serotype-specific ELISAs using novel monoclonal antibodies.

Kuck D, Kern A, Kleinschmidt JA.

J Virol Methods. 2007 Mar;140(1-2):17-24. Epub 2006 Nov 28.

PMID:
17126418
36.

Isolation of targeted AAV2 vectors from novel virus display libraries.

Waterkamp DA, Müller OJ, Ying Y, Trepel M, Kleinschmidt JA.

J Gene Med. 2006 Nov;8(11):1307-19.

PMID:
16955542
37.

Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1.

Kuck D, Lau T, Leuchs B, Kern A, Müller M, Gissmann L, Kleinschmidt JA.

J Virol. 2006 Mar;80(6):2621-30.

38.

Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors.

Müller OJ, Leuchs B, Pleger ST, Grimm D, Franz WM, Katus HA, Kleinschmidt JA.

Cardiovasc Res. 2006 Apr 1;70(1):70-8. Epub 2006 Jan 31.

PMID:
16448634
39.

Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly.

Kuck D, Leder C, Kern A, Müller M, Piuko K, Gissmann L, Kleinschmidt JA.

Vaccine. 2006 Apr 5;24(15):2952-65. Epub 2005 Dec 29.

PMID:
16414157
40.
41.

A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini.

Kronenberg S, Böttcher B, von der Lieth CW, Bleker S, Kleinschmidt JA.

J Virol. 2005 May;79(9):5296-303.

43.

Residues within the B' motif are critical for DNA binding by the superfamily 3 helicase Rep40 of adeno-associated virus type 2.

Yoon-Robarts M, Blouin AG, Bleker S, Kleinschmidt JA, Aggarwal AK, Escalante CR, Linden RM.

J Biol Chem. 2004 Nov 26;279(48):50472-81. Epub 2004 Sep 14.

44.

Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.

Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, Büning H, Hallek M.

Gene Ther. 2003 Dec;10(26):2139-47.

PMID:
14625569
45.

Identification of a heparin-binding motif on adeno-associated virus type 2 capsids.

Kern A, Schmidt K, Leder C, Müller OJ, Wobus CE, Bettinger K, Von der Lieth CW, King JA, Kleinschmidt JA.

J Virol. 2003 Oct;77(20):11072-81.

46.

Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors.

Müller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Kleinschmidt JA, Trepel M.

Nat Biotechnol. 2003 Sep;21(9):1040-6. Epub 2003 Aug 3.

PMID:
12897791
48.

The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity.

Girod A, Wobus CE, Zádori Z, Ried M, Leike K, Tijssen P, Kleinschmidt JA, Hallek M.

J Gen Virol. 2002 May;83(Pt 5):973-8.

PMID:
11961250
49.

Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids.

Kronenberg S, Kleinschmidt JA, Böttcher B.

EMBO Rep. 2001 Nov;2(11):997-1002.

50.

Supplemental Content

Loading ...
Support Center